What is cytoreductive therapy, its primary purpose, and first‑line treatment options?

What is Cytoreductive Therapy?

Cytoreductive therapy is pharmacological treatment that reduces elevated blood cell counts in myeloproliferative neoplasms (MPNs), primarily used to prevent thrombotic complications and control disease-related symptoms such as splenomegaly, pruritus, and progressive leukocytosis. 1

Primary Purpose

The main goals of cytoreductive therapy are to:

• Prevent thrombosis (the primary cause of morbidity and mortality in polycythemia vera and essential thrombocythemia)
• Control disease-related symptoms including symptomatic splenomegaly, severe pruritus, night sweats, and fatigue
• Normalize blood counts when phlebotomy alone is insufficient or poorly tolerated
• Reduce the risk of hemorrhagic complications when platelet counts exceed 1,500 × 10⁹/L 2

Cytoreductive therapy does NOT prevent transformation to myelofibrosis or acute myeloid leukemia with current available agents 3.

Who Needs Cytoreductive Therapy

High-Risk Patients (Mandatory Treatment)

Cytoreduction is strongly recommended for:

• Age ≥60 years, OR
• Prior history of thrombosis 4, 1

Additional Indications (Regardless of Age)

Initiate cytoreductive therapy when patients develop:

• New thrombosis or disease-related major bleeding
• Poor tolerance to phlebotomy or frequent phlebotomy requirement (≥3 per year may increase thrombotic risk)
• Symptomatic or progressive splenomegaly
• Severe disease-related symptoms (pruritus, night sweats, fatigue)
• Platelet count >1,500 × 10⁹/L (bleeding risk)
• Progressive leukocytosis (leukocyte count >15 × 10⁹/L in PV)
• Symptomatic thrombocytosis 4, 1

Low-Risk Patients (Age <60, No Prior Thrombosis)

Cytoreductive therapy is NOT recommended as initial treatment in asymptomatic low-risk patients with well-controlled cardiovascular risk factors 4, 2. These patients should be managed with phlebotomy (maintaining hematocrit <45%) and low-dose aspirin (81-100 mg daily) 4, 1.

First-Line Treatment Options

For Polycythemia Vera

Either hydroxyurea OR recombinant interferon alpha (rIFNα) is first-line cytoreductive therapy at any age 1. The choice depends on:

Hydroxyurea:

• Preferred in older patients
• Use with caution in patients <40 years due to theoretical leukemogenic concerns
• Typical starting dose: 15-20 mg/kg/day, titrated to response
• Monitor for resistance/intolerance criteria 2

Recombinant Interferon Alpha:

• Preferred in young patients requiring long-term treatment
• Non-leukemogenic
• Can induce molecular responses (decreased JAK2V617F allele burden)
• Higher discontinuation rate due to toxicity (5.2% annually) 5

Busulfan:

• May be considered only in very elderly patients (>70 years) with short life expectancy
• Associated with increased risk of acute leukemia and second malignancies 1, 4, 2

For Essential Thrombocythemia

Hydroxyurea is the first-line cytoreductive therapy at any age, though use should be carefully considered in patients <40 years 1, 2. The recommendation is based on the UK-PT1 trial showing superiority of hydroxyurea plus aspirin over anagrelide plus aspirin in preventing thrombotic complications.

Common Pitfalls and Caveats

Critical Warning: Patients who develop resistance or intolerance to hydroxyurea have a 5.6-fold increase in mortality and 6.8-fold increased risk of transformation to myelofibrosis or acute myeloid leukemia 6. These patients require prompt transition to second-line therapy.

Hydroxyurea Resistance/Intolerance Criteria:

• Need for phlebotomy to maintain hematocrit <45% after 3 months of ≥2 g/day hydroxyurea
• Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months of ≥2 g/day
• Development of cytopenia at lowest effective dose
• Leg ulcers or unacceptable mucocutaneous toxicity 2

Aspirin Considerations:

• All PV patients should receive low-dose aspirin (81-100 mg daily) unless contraindicated
• Withdraw aspirin if major bleeding occurs (most commonly gastrointestinal)
• In ET, aspirin is indicated if microvascular disturbances are present 2, 1, 2

Avoid Sequential Cytotoxic Agents: Patients receiving more than one cytotoxic agent have significantly higher risk of developing acute myeloid leukemia/myelodysplastic syndromes 2.